An observational study in Lung Carcinoma, sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 400 studies in Lung Neoplasms with a site in France — 114 open to participants now, 150 under way, 26 of them phase 3. Lung Neoplasms · France.
Among the 400 studies in Lung Neoplasms with a site in France, this one is the 69th largest by enrollment of the 105 observational ones that give a count, is one of 33 that started in 2025, is one of 105 observational ones, and was the 355th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →114 of the 400 studies in Lung Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Leon Berard · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
Centre Hospitalier Henri Duffaut - Avignon · Sites in France
Ages 18+
SystImmune Inc. · Sites in France, United States, Australia and 13 more countries
Ages 18+
Bristol-Myers Squibb · Sites in France, United States, Belgium and 10 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
400 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 88 · Phase 3 69 · Phase 4 8
First in 1993; this study’s year is marked. 33 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 170 across the 291 interventional studies, 190 across the 105 observational. Of the 217 that completed or were terminated, 49 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 400 have an industry lead sponsor. The 10 most frequent:
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Lung Neoplasms with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT04380636Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | 2027-05-05 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 34 to your calendar (.ics) → With an account.
Among the 400 studies in Lung Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bronchial cancer is a major oncological pathology, representing the leading cause of cancer death in France. Supportive oncological care (SOS) is defined as all the care and support necessary for patients throughout their journey, in addition to specific treatments. Despite their importance, their identification and accessibility remain heterogeneous in outpatient oncology. This single-center observational study aims to describe the supportive care needs of patients with bronchial cancer in the active phase of treatment at the Nord-Ouest Hospital in Villefranche-sur-Saône. A self-questionnaire based on the national SOS identification grid will be offered to 100 patients followed in thoracic oncology. The main objective is to identify priority needs perceived and expressed by patients, particularly in terms of psychological support, pain management, nutrition, physical activity, fatigue and social impact. Secondary objectives include the evaluation of the proposal and acceptance of SOS by patients, the analysis of the causes of refusal and the study of variations in needs according to the temporality of treatments and demographic characteristics. A descriptive statistical analysis will be carried out, supplemented by comparative tests to explore the relationships between identified needs and patient profiles. The expected results will make it possible to optimize the provision of supportive care in outpatient oncology, by proposing strategies adapted to the specific needs of patients with bronchial cancer.
Bronchial cancer is a leading oncological pathology, representing the leading cause of cancer death in France. In 2023, there were 52,777 new cases, with a downward trend in men but a notable increase in women. Despite therapeutic advances, this pathology remains associated with high morbidity and a significant impairment of patients' quality of life. Supportive oncological care is defined as all the care and support necessary for patients throughout their journey, in addition to specific oncological treatments. The national framework for supportive oncological care (2021) highlights their essential role in improving the quality of life of patients with cancer, but their evaluation and proposal remain heterogeneous, particularly in outpatient oncology. In this context, this single-center observational study aims to describe the supportive care needs of patients with bronchial cancer in the active phase of treatment at the Nord-Ouest Hospital in Villefranche-sur-Saône.
A self-questionnaire inspired by the national grid for identifying supportive oncological care will be offered to 100 patients followed in thoracic oncology. The main objective is to identify priority supportive care needs, whether perceived by professionals or expressed directly by patients. This identification will concern several areas: understanding the disease and treatments, pain management, psychological support, nutrition, physical activity, fatigue, sleep, maintaining social and professional life, sexuality and lifestyle habits. The study will also focus on the supportive care actually offered and its acceptance by patients, in order to assess possible disparities between the needs identified and the existing offer.
Secondary objectives include the analysis of the causes of refusal of supportive care, the evaluation of patient satisfaction with the existing offer and the study of the influence of the temporality of treatments on the evolution of needs. The study will also seek to determine whether these needs vary based on certain demographic characteristics such as age and gender.
From a methodological point of view, the data will be analyzed using a descriptive and comparative approach. The results will be expressed in frequencies and percentages for qualitative variables, and in means or medians for quantitative variables. Appropriate statistical tests will make it possible to compare groups and identify factors influencing the variability of needs.
The study will take place over a period of one month, with inclusion planned for February 2025 and completion in March 2025. Each patient will participate in the study over a single day, corresponding to the completion of the self-questionnaire during an outpatient oncology consultation. The questionnaire will be distributed by the investigator and can be completed with the help of a caregiver if necessary.
The expected results will make it possible to optimize the provision of outpatient oncology supportive care, by identifying unmet needs and obstacles to access to this care. They could also contribute to the implementation of improvement strategies adapted to the specificities of patients with bronchial cancer, in order to ensure more complete and personalized care.
Adult patient suffering from lung cancer and followed in the outpatient oncology department of the HNOV
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
population of 100 adults followed in the outpatient oncology department for lung cancer who are given a self-questionnaire on their need for supportive care after delivery of an information notice and collection of their non-opposition, over the period from February to April 2025.
Proportion of Patients Reporting Unmet Supportive Care Needs Using a Standardized Identification Grid.
Assessment of supportive care needs in patients with bronchial cancer using a standardized first-level identification grid. Needs will be categorized (e.g., psychological, nutritional, pain management, social support) and reported as the proportion of patients identifying at least one unmet need in each category.
Time frame: At the time of outpatient consultation (Day 0)
Evaluate whether supportive care is offered by the healthcare team and accepted by patients.
Binary judgment criteria (yes/no) to additional questions added to the INCA reference grid
Time frame: At the time of outpatient consultation (Day 0)
Analyze the causes of refusal of help by patients and evaluate the satisfaction of the supportive care offer
Answers to questions about the benefit of meeting a professional; managing the situation without help; sufficient advice and open responses and the rate of "unsatisfied" patient responses less than 5%
Time frame: At the time of outpatient consultation (Day 0)
Plan to share: Undecided — compliance with the regulations of the Data Protection Act, no transfer to the EU to respect the commitment to conform to the CNIL reference methodology MR-03.
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Mar 2025, 1 month.
Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's 1 month is below that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône